Pages that link to "Q42551246"
Jump to navigation
Jump to search
The following pages link to Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice (Q42551246):
Displaying 50 items.
- Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself? (Q22306448) (← links)
- Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release (Q24647299) (← links)
- Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy (Q24675327) (← links)
- Why there are two cyclooxygenase isozymes (Q27863307) (← links)
- CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor (Q28116204) (← links)
- Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans (Q28174827) (← links)
- Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement (Q28175558) (← links)
- Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans (Q28184229) (← links)
- Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers (Q28184249) (← links)
- Delay in oral mucosal ulcer healing by aspirin is linked to the disturbances in p38 mitogen-activated protein kinase activation (Q28186400) (← links)
- The role of cyclooxygenase in gastric mucosal protection (Q28192148) (← links)
- Cyclo-oxygenase isoenzymes. Structural basis for selective inhibition of cyclo-oxygenases by anti-inflammatory agents (Q28192303) (← links)
- Selective cyclo-oxygenase-2 inhibitors: cardiovascular and gastrointestinal toxicity (Q28192305) (← links)
- Management of peptic ulcer disease not related to Helicobacter (Q28192901) (← links)
- Effect of H. pylori infection on the expression of cyclooxygenase-2 in human gastric mucosa (Q28194686) (← links)
- Relative contribution of acetylated cyclooxygenase (COX)‐2 and 5‐lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin (Q28195729) (← links)
- Mucosa protective therapy with long-term nonsteroidal antirheumatic drugs (Q28199428) (← links)
- Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond (Q28210656) (← links)
- Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis (Q28214002) (← links)
- Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin (Q28219464) (← links)
- Non-opioid analgesics for perioperative pain therapy. Risks and rational basis for use (Q28250553) (← links)
- Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach (Q28343775) (← links)
- Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence (Q28344081) (← links)
- Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge (Q28361239) (← links)
- Plaunotol prevents indomethacin-induced gastric mucosal injury in rats by inhibiting neutrophil activation (Q28374016) (← links)
- Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions (Q28377539) (← links)
- Expression of cyclooxygenase (COX)-1 and COX-2 in adaptive cytoprotection induced by mild stress (Q28378167) (← links)
- Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors (Q28573632) (← links)
- The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts (Q31371704) (← links)
- Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats. (Q32078167) (← links)
- COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice (Q33223568) (← links)
- Integrative roles of transforming growth factor-alpha in the cytoprotection mechanisms of gastric mucosal injury (Q33252380) (← links)
- The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study (Q33333061) (← links)
- Selective COX-2 inhibitors: is the water becoming muddy? (Q33547873) (← links)
- Three-dimensional tissue assemblies: novel models for the study of Salmonella enterica serovar Typhimurium pathogenesis. (Q33553824) (← links)
- NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression (Q33701847) (← links)
- When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations (Q33758859) (← links)
- Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). (Q33813180) (← links)
- Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events (Q33813213) (← links)
- The role of cyclooxygenases in inflammation, cancer, and development (Q33814331) (← links)
- Basic biology and clinical application of specific cyclooxygenase-2 inhibitors (Q33822140) (← links)
- Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. (Q33938703) (← links)
- Eicosanoids and the stomach (Q33950285) (← links)
- An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. (Q33952311) (← links)
- COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages? (Q33959080) (← links)
- Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy (Q33994040) (← links)
- COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation? (Q33998294) (← links)
- Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity. (Q34008670) (← links)
- Aspirin and other anti-inflammatory drugs (Q34036177) (← links)
- Nonsteroidal anti-inflammatory drugs (Q34057579) (← links)